ABSTRACT
In the EORTC classification two types of primary cutaneous large B-cell lymphoma (PCLBCL) are distinguished: primary cutaneous follicle center cell lymphomas (PCFCCL) and PCLBCL of the leg (PCLBCL-leg). Distinction between both groups is considered important because of differences in prognosis (5-year survival >95% and 52%, respectively) and the first choice of treatment (radiotherapy or systemic chemotherapy, respectively), but is not generally accepted.
To establish a molecular basis for this subdivision in the EORTC classification we investigated the gene expression profiles of 21 PCLBCL by oligonucleotide microarray analysis. Hierarchical clustering based on a B-cell signature (7450 genes) classified PCLBCL into two distinct subgroups consisting of respectively 8 PCFCCL and 13 PCLBCL-leg.
PCLBCL-leg showed increased expression of genes associated with cell proliferation, the proto-oncogenes Pim-1, Pim-2 and c-Myc, and the transcription factors Mum1/IRF4 and Oct-2. In the group of PCFCCL high expression of SPINK2 was observed. Further analysis suggested that PCFCCL and PCLBCL-leg have expression profiles similar to that of germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphoma, respectively. The results of this study suggest that different pathogenetic mechanisms are involved in the development of PCFCCL and PCLBCL-leg and provide molecular support for the subdivision used in the EORTC classification.
only.
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INTRODUCTION
The term primary cutaneous B-cell lymphomas refers to a heterogeneous group of B-cell neoplasms, which present in the skin without evidence of extracutaneous disease.
1 A significant proportion of these primary cutaneous B-cell lymphomas are large cell lymphomas. [2] [3] [4] [5] In the European Organization for Research and Treatment of Cancer (EORTC)
classification for primary cutaneous lymphomas, two main groups of primary cutaneous large B-cell lymphomas (PCLBCL) are distinguished. 1 Most cases are included in the group of primary cutaneous follicle center cell lymphomas (PCFCCL). Histologically, these PCFCCL represent a spectrum with variable proportions of (small) centrocytes and centroblasts and sometimes a follicular growth pattern in early lesions, and diffuse infiltrates of generally large centrocytes (large cleaved cells) in tumorous lesions. [2] [3] [4] [5] In the WHO classification such early lesions are classified as cutaneous follicle center lymphoma, whereas the tumorous lesions are classified as diffuse large B-cell lymphoma. 6 Clinically, these PCFCCL represent a welldefined group of primary cutaneous B-cell lymphomas which often present with skin lesions confined to a limited skin area on the head or the trunk, rarely disseminate to extracutaneous sites, and -irrespective of the proportion of large cells or growth pattern-have an excellent prognosis (5-year survival of more than 95%). 1, 7 Already in the first publication on this group of PCFCCL it was noted that patients presenting with skin tumors on the leg had a different clinical behaviour. 3 Recent studies demonstrated that patients with such a primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg) differ from PCFCCL by a higher age of onset, more frequent dissemination to extracutaneous sites, and a poorer prognosis (5-year survival of approximately 50%). 7, 8 Histologically, these PCLBCL-leg show a predominance of tumor cells with round nuclei and, in contrast to the group of PCFCCL, strongly express Bcl-2 protein. [7] [8] [9] [10] For these reasons these PCLBCL-leg were included as a separate entity in only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013 . bloodjournal.hematologylibrary.org From the EORTC classification. 1 Distinction between these two types of PCLBCL is clinically important, since it dictates the first choice of treatment: radiotherapy in PCFCCL and anthracycline-based chemotherapy in PCLBCL-leg. 7 By following the WHO classification both groups will be lumped together in the group of diffuse large B-cell lymphoma, and all patients will be treated with anthracycline-based chemotherapy with or without radiotherapy.
Although recent studies [11] [12] [13] confirmed that these PCLBCL-leg are a distinct group with an intermediate prognosis, the subdivision of primary cutaneous B-cell lymphomas into two main categories (PCLBCL-leg and PCFCCL) primarily based on site of presentation (leg versus other sites) has been much disputed.
14 Recent studies have started to evaluate the genetic mechanisms involved in the development and progression of these lymphomas. However, the number of studies published to date is still limited and specific cytogenetic abnormalities have not been identified yet. Most studies have focused on the differential expression of the Bcl-2 protein in the different groups of PCLBCL.
Most authors agree that the Bcl-2 overexpression in the group of PCLBCL-leg is not associated with the t(14;18) translocation as observed in most follicular and some diffuse large B-cell lymphomas in lymph nodes. 9, 14, 16 In some cases it might result from chromosomal amplification of the Bcl-2 gene. 17, 18 Recent comparative genomic hybridization (CGH) studies demonstrated 6q loss and 18q gain in a proportion of PCLBCL, but not in PCFCCL. 18 Inactivation of p15 and p16 tumor suppressor genes by promoter hypermethylation has been detected in 11% and 44% of PCLBCL, respectively.
19
In the present study we performed oligonucleotide microarray analysis on a large group of PCLBCL, including 8 PCFCCL and 13 PCLBCL-leg. The main purpose of this study was to find out if the two types of PCLBCL recognized in the EORTC classification have different gene expression profiles. Differences in the gene expression profiles might not only give insight in the pathogenetic mechanisms underlying the differences in clinical behavior only.
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MATERIALS AND METHODS

Patient selection
Pretreatment skin biopsies from 8 patients with PCFCCL with a diffuse large cell histology and 13 patients with PCLBCL-leg were included in this study. Only cases in which large neoplastic B-cells constituted 80% or more of the total number of infiltrating cells were selected. The diagnosis PCFCCL or PCLBCL-leg was based on the criteria of the EORTC classification. 1 Using the WHO-classification all cases were classified as diffuse large B-cell lymphoma. 6 In all patients there was no evidence of extracutaneous disease at time of diagnosis as assessed by adequate staging procedures including physical examination, complete blood cell counts, computed tomography of chest and abdomen and bone marrow biopsy.
Patients with a PCFCCL presented with localized skin lesions either on the scalp (5 cases) or trunk (3 cases). Histologically, seven cases showed a diffuse proliferation of predominantly large cleaved cells (large centrocytes), whereas in one case (no. 1) almost equeal numbers of large cleaved cells and large non-cleaved cells (centroblasts) were observed. In one case (no.
6) small clusters of CD35+ follicular dendritic cells were seen suggesting a preceding follicular growth pattern. Immunostaining showed 15-20% (median 20%) admixed T-cells and few scattered CD68+ macrophages. Consistent with previous studies of our group the neoplastic B-cells were either completely negative for Bcl-2 protein or showed a weak staining on a minor proportion (<20%) of tumor cells.
The 13 patients with a PCLBCL-leg presented with skin tumors on one (11 cases) or both legs (2 cases) ( 
Oligonucleotide microarrays
Samples and microarrays were processed according to the manufacturer's protocol (available from Affymetrix, Santa Clara, CA, USA). In brief, on average between 20-60 µg RNA was isolated from 50 x 20 µm frozen sections with the RNeasy-kit (Qiagen,Hilden, Germany).
Using the MessageAmp aRNA kit (Ambion, Huntingdon, United Kingdom) total RNA was reverse transcribed using an oligo(dT)-T7 promoter primer to prime first strand synthesis.
After second strand synthesis, the purified cDNA product was in vitro transcribed using T7 RNA polymerase, biotin-UTP and biotin-CTP to generate fragmented biotinylated aRNA.
Fragmented aRNA (15 µg) was hybridized to a Human Genome U95Av2 Array (Affymetrix), interrogating 12625 human transcripts, for 16 h at 45°C with constant rotation at 60 rpm.
After hybridization, the microarray was washed, stained on an Affymetrix fluidics station and scanned with an argon-ion confocal laser with 488 nm excitation and 570 nm detection wavelengths.
Data processing and analysis
The array images were quantified utilizing the MicroArray Suite (MAS) v5.0 software (Affymetrix, Santa Clara, CA, USA). The average fluorescence intensity was determined for each microarray and then the output of each experiment was globally scaled to a target value of 200. Normalization of the data was performed using variant stability and normalization For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From transcripts and for the housekeeping genes U1A and RPS11 used for normalization were as follows: denaturing for 15 s at 95°C; annealing and extension for 60 s at 60°, for 40 cycles.
The primer sequences (Invitrogen) of selected transcripts are given in Table 2 . For analysis of Bcl-2 expression primer combinations detecting 2 different splice variants (Bcl-2 alpha and Bcl-2 beta) were used. 24 Data were evaluated using the SDS software version 1.9.1 (Applied Biosystems) and the second derivative maximum algorithm. Specificity of the PCR product 
Differentially expressed genes in PCLBCL
Expression profiles of the entire set of genes of the 8 PCFCCL samples and the 13 PCLBCLleg samples were compared using the significance analysis of microarrays (SAM) technique to identify most differentiating genes between both groups. In this analysis all 12625 genes were included in order not to miss genes aberrantly expressed by tumor cells or genes that are expressed in late stages of B-cell differentiation (e.g. plasma cells), which are not covered by the generated B-cell signature. Seventy-one statistically significant differentially expressed genes at p<0.01 were identified as most discriminating genes between PCFCCL and PCLBCL-leg with fold changes of at least 3.0. Of these 71 most discriminating genes between PCFCCL and PCLBCL-leg, 48 genes were highly expressed in the group of PCLBCL-leg and 23 genes were up-regulated in the group of PCFCCL as visualized in Figure 2 . outcome was not present in PCLBCL-leg. 25, 26 To investigate proliferation rates of PCLBCL paraffin sections of the same tumors were also stained with an antibody against the proliferation marker Ki-67. Whereas Ki-67 was expressed by more than 75% of the tumor cells in all PCLBCL-leg, Ki-67 staining in PCFCCL was much more variable with percentages varying between 10% and 80% (median, 
DISCUSSION
In the EORTC classification of cutaneous lymphomas two types of PCLBCL are recognized:
PCFCCL and PCLBCL-leg. The clinical, histological, immunophenotypical and genetic differences between both groups are summarized in Table 3 . Although recent studies have provided further support for the clinical significance of this classification, there is still ongoing debate regarding the subdivision of PCLBCL into two main categories primarily based on site of presentation. [18] [19] [20] Understanding of the genetic mechanisms involved in the development and progression of these lymphomas might provide a solution for this controversy.
In the present study gene expression profiles of 8 PCFCCL with a diffuse large cell histology and 13 PCLBCL-leg were generated using Affymetrix® oligonucleotide arrays. In the group of PCFCCL very high expression levels of the SPINK2 transcript were observed in all samples, except one, whereas expression of SPINK2 was very low or absent in all samples of PCLBCL-leg. Interestingly, SPINK2 was identified as the most differentially expressed gene between both groups with a remarkable high fold change of 17.0.
Furthermore, SPINK2 was recognized as one of the genes of the germinal center genes of the 43 genes which discriminate between the GCB and ABC types of DLBCL with highest significance. 28 The SPINK2 gene encodes a Kazal type serine threonine kinase with illdefined function in physiological and pathological cellular processes. 45 Further studies will be needed to elucidate the potential role of SPINK2 in the development of PCFCCL. In addition, several genes associated with the host immune response (granzyme M, selectin P, Lck) were substantially upregulated in the group of PCFCCL, which is consistent with the higher numbers of host immune cells in these tumors. This is also in line with previous observations in diffuse large B-cell lymphomas that genes associated with the host immune response and extracellular matrix components (both were considered part of the "lymph node signature") are more highly expressed in GCB tumors 46 Consistent with previous studies 9, 10 we observed strong Bcl-2 protein expression in 11 of 13 PCLBCL-leg, but not in the PCFCCL included for this study. Bcl-2 encoding mRNA expression values, however, did not statistically significantly differ between the two groups;
Bcl-2 mRNA was detected in all patients both by using the microarray analysis (not discriminating between both splice variants) as well as qPCR analysis (for each individual splice variant). The presence of Bcl-2 mRNA despite the absence of Bcl-2 protein in the group of PCFCCL was unexpected, but has previously been described as a characteristic feature of germinal center B cells. 49, 50 It was suggested that germinal center cells may be involved in some arrest of Bcl-2 protein expression at the posttranscriptional level. 47, 48 Such only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From a, hitherto unknown, mechanism might be conserved in PCFCCL and reflect a typical feature of its proposed germinal center B-cell origin. The mechanisms underlying the high bcl-2 protein expression in PCLBCL-leg are at present unknown. Posttranslational modification such as ubiquitination of kinase sites or decreased degradation, for instance by inhibition of FRAP/RAFT/mTOR, leading to increased cellular concentration of bcl-2 protein unrelated to the amount of Bcl-2 mRNA might be a possible explanation. 49, 50 In conclusion, the results of the present study provide molecular support for the view that PCFCCL and PCLBCL-leg are distinct subtypes of PCLBCL, as recognized in the EORTC classification. They also suggest different mechanisms of malignant transformation in these two types of PCLBCL. The observation that PCFCCL and PCLBCL-leg have gene expression profiles similar to that of GCB and ABC type of diffuse large B-cell lymphoma is clinically important. It is not only consistent with the much better prognosis of the group of PCFCCL, but also suggest that different therapeutic approaches are warranted in these two types of PCLBCL.
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